| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1092852900021519 |
| P698 | PubMed publication ID | 17805214 |
| P50 | author | Joseph Biederman | Q6281524 |
| Gagan Joshi | Q93001751 | ||
| Megan Aleardi | Q114572757 | ||
| Janet Wozniak | Q114735122 | ||
| P2093 | author name string | Robert Doyle | |
| Paul Hammerness | |||
| Eric Mick | |||
| Thomas Spencer | |||
| Megan Kotarski | |||
| P2860 | cites work | A rating scale for mania: reliability, validity and sensitivity | Q29619299 |
| Mania-Like Symptoms Suggestive of Childhood-Onset Bipolar Disorder in Clinically Referred Children | Q34303286 | ||
| The Mania Rating Scale (MRS): further reliability and validity studies with children | Q34381872 | ||
| The Mania Rating Scale: can it be used in children? A preliminary report | Q34382865 | ||
| The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review | Q36015766 | ||
| Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. | Q36026701 | ||
| Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials | Q36466463 | ||
| An open-label trial of risperidone in children and adolescents with bipolar disorder | Q40420633 | ||
| A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder | Q40680619 | ||
| Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial | Q44385585 | ||
| Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study | Q44495168 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children | Q46765699 | ||
| Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. | Q50302507 | ||
| Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation. | Q51907028 | ||
| Suicide among female adolescents: characteristics and comparison with males in the age group 13 to 22 years. | Q52013366 | ||
| New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. | Q53993918 | ||
| Risperidone in adolescents with schizophrenia: an open pilot study | Q73308908 | ||
| Factor structure of the Young Mania Rating Scale for use with youths ages 5 to 17 years | Q78434781 | ||
| A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania | Q82844588 | ||
| P433 | issue | 9 | |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 683-689 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | C N S Spectrums | Q15750260 |
| P1476 | title | An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder | |
| P478 | volume | 12 |
| Q37653402 | A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. |
| Q39469844 | A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents |
| Q41938580 | Adolescent with tourette syndrome and bipolar disorder: a case report |
| Q28073540 | Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis |
| Q33858314 | Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study |
| Q45990613 | Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. |
| Q43254593 | Diagnosis and treatment of comorbidities of Tourette's syndrome and bipolar disorder in a 10-year-old boy. |
| Q88404910 | Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study |
| Q36075828 | Efficacy and safety of aripiprazole in child and adolescent patients |
| Q37299210 | Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review |
| Q34611306 | Focus on aripiprazole: a review of its use in child and adolescent psychiatry |
| Q35242995 | High level of persistence of pediatric bipolar-I disorder from childhood onto adolescent years: a four year prospective longitudinal follow-up study |
| Q34613057 | Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders |
| Q37131034 | Pediatric bipolar disorder: recognition in primary care |
| Q46185243 | Pharmacotherapy in bipolar disorders during childhood and adolescence |
| Q37742068 | Pharmacotherapy of bipolar disorder in children and adolescents: recent progress |
| Q33819889 | Prescribing patterns for treatment of pediatric bipolar disorder in a specialty clinic |
| Q34600500 | Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents |
| Q36853126 | Prolactin serum concentrations during aripiprazole treatment in youth |
| Q34486230 | Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial |
| Q38090490 | Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review |
Search more.